Different Phenotypes of Bronchiectasis

Brief Title

Different Phenotypes of Bronchiectasis

Official Title

Different Phenotypes of Bronchiectasis

Brief Summary

      Bronchiectasis is defined as abnormal chronic dilatation of one or more bronchi. Patients
      have a structural abnormality of the bronchial wall that predisposes them to bacterial
      infection likely due to impaired mucus clearance. A vicious cycle of chest infections and
      chronic lung inflammation can lead to further damage of the bronchial wall and spread of
      disease to normal areas of bystander lung.

Detailed Description

      A search for an underlying cause, which may be amenable to a targeted intervention to prevent
      ongoing damage, is essential but often fruitless, and the focus of therapy rapidly turns to
      empiric treatments to prevent infective exacerbations and retard disease progression. The
      British Thoracic Society Bronchiectasis management guidelines provide an in-depth summary of
      the available literature and are an excellent tool for guiding treatment decision making.
      However, they do not provide guidance on which patients are most likely to benefit from
      specific interventions.Disease severity in bronchiectasis is hard to define. Radiological
      severity grading scores exist; however, there is often a disconnect between radiological
      severity, symptom burden and disease progressionIn 2014, competing bronchiectasis severity
      scores were published (FACED and the Bronchiectasis Severity Index (BSI).

      In each of these, a combination of patient demographics, symptom scores, comorbidities, and
      clinical, radiological and microbiological parameters were used to construct scoring systems.

      In case of the BSI, it predicted future mortality, and in the case of FACED, extended to
      prediction of future exacerbation frequency, hospitalisation and quality of life.These
      severity scores have utility in identifying an individual's risk of disease progression to a
      predefined outcome and aid in sub classifying this heterogeneous group of patients in a
      manner that may pave the way to future mechanistic studies, which explain how these different
      disease phenotypes arise and inform the development of targeted therapeutics.

Study Type

Observational

Primary Outcome

( Severity of Bronchiectasis will be measured according to BSI scoring system and FACED scoring system

Secondary Outcome

 management of bronchectasis according to severity index

Condition

Bronchiectasis

Intervention

Pulmonary function tests,Bronchiectasis severity index score

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Combination Product

Estimated Enrollment

Start Date

July 1, 2017

Completion Date

January 1, 2019

Primary Completion Date

September 1, 2018

Eligibility Criteria

        Inclusion Criteria:

        patient diagnosed as bronchiectasis according to clinical picture and high- resolution
        computed tomography scan of the chest.

        can perform pulmonary function test.

        Exclusion Criteria:

        No

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Maha El-kholy, Prof, ,

Location Countries

Egypt

Location Countries

Egypt

Administrative Informations

NCT ID

NCT03262064

Organization ID

DPOB

Responsible Party

Principal Investigator

Study Sponsor

Assiut University

Study Sponsor

Maha El-kholy, Prof, Study Director,

Verification Date

September 2017